SynthesisFrontiers in pediatrics2025
Prevalence of survival without major morbidity and associated risk factors among very preterm infants: a systematic review and meta-analysis.
Synthesis in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Preterm Neonatal Mortality and Its Associated Factors in Ethiopia: A Systematic Review and Meta-Analysis.Health science reports · 2026Review
- Survival without major morbidity in extremely preterm infants: a prospective multicenter study in Shenzhen, China.Frontiers in pediatrics · 2026Article
- Survival without major morbidity in very preterm infants (<32 weeks' gestation): prevalence, temporal trends, and associated factors in a single-center retrospective cohort.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Survival without major morbidity (SWMM) in very preterm infants represents a critical outcome measure in neonatal care. This systematic review evaluates both the prevalence of SWMM among infants born before 32 weeks' gestation and the associated risk factors. Methods: We conducted a comprehensive search of PubMed, Web of Science, Embase, Cochrane Library, Scopus, CNKI, CBM, and Wanfang databases from inception through February 4, 2025. Two independent reviewers performed study selection and data extraction. Study quality was assessed using the Agency for Healthcare Research and Quality (AHRQ) checklist for cross-sectional studies and the Newcastle-Ottawa Scale (NOS) for cohort studies. Pooled prevalence was calculated using a random-effects model. Heterogeneity was explored through subgroup analyses and meta-regression, and publication bias was assessed via funnel plots and further evaluated with trim-and-fill analysis. Risk factors were evaluated using multivariate meta-analysis of adjusted odds ratios (ORs) with 95% confidence intervals (CIs). Results: From 1,606 screened articles, 35 studies spanning twelve countries met inclusion criteria. The pooled SWMM incidence was 47% (95% CI: 40%-54%), with notable gestational age stratification: 67% (95% CI: 62%-72%) for infants <32 weeks vs. 44% (95% CI: 26%-61%) for those <28 weeks. Meta-analysis identified gestational age maturity (OR: 1.65; 95% CI: 1.50-1.81), antenatal corticosteroid administration (OR: 1.46; 95% CI: 1.12-1.89), and higher 5-minute Apgar scores (OR: 1.21; 95% CI: 1.06-1.37) as positive predictors of SWMM. Conversely, male sex (OR: 0.62; 95% CI: 0.55-0.71) and hemodynamically significant patent ductus arteriosus (OR: 0.51; 95% CI: 0.38-0.69) showed negative associations with SWMM. Conclusion: The review reports a 47% SWMM rate among very preterm infants, with higher rates observed in infants of later gestational age. Key predictors include gestational age, 5-minute Apgar score, and antenatal corticosteroids, while male sex and patent ductus arteriosus are associated with reduced SWMM. Limitations include heterogeneity in SWMM definitions and geographic variability. Future research should focus on standardizing outcome measures and validating risk factors through multinational studies. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025641924, PROSPERO CRD42025641924.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.